BioLineRx Changes American Depositary Shares Ratio
BioLineRx Ltd. (NASDAQ: BLRX), a dedicated player in the biopharmaceutical industry, recently made headlines with an important decision regarding its American Depositary Shares (ADS). The company's Board of Directors has approved a significant adjustment to the ratio of its ordinary shares represented by ADSs from 15 ordinary shares per ADS to an impressive 600 ordinary shares per ADS. This change not only streamlines their share structure but also points towards a more strategic approach in navigating the fluctuating market landscape.
Understanding the Impact of the New Exchange Ratio
The new exchange ratio, which functions similarly to a 1-for-40 reverse stock split of the ADSs, is expected to reduce the number of outstanding ADSs dramatically from over 142 million to about 3.5 million. This recalibration aims to enhance the trading suitability of BioLineRx's ADSs on the Nasdaq Capital Market. Investors should anticipate an adjustment in the trading price of the ADSs to reflect this new ratio.
Reasons Behind the Decision
The change is particularly significant as it follows a recent out-licensing transaction with Ayrmid Ltd. and represents a calculated step to bolster the company's market standing. With robust cash resources of approximately $29.5 million, BioLineRx feels confident about maintaining operational momentum through the latter half of 2026. This financial stability will support ongoing clinical developments, including critical work on motixafortide for pancreatic cancer, which is part of their extensive pipeline.
Quote from the CEO
Philip Serlin, Chief Executive Officer of BioLineRx, emphasized, "This ratio adjustment is crucial for our long-term strategy, particularly for securing our Nasdaq listing, which remains essential for our growth. By addressing the low-priced stock rule set forth by the Nasdaq, we aim to enhance our compliance with listing standards and continue to enjoy the benefits that come with our exchange status."
Technical Details for ADS Holders
Importantly, this change will not affect holders of BioLineRx's ordinary shares on the Tel Aviv Stock Exchange, which will remain as is. For ADS holders, there will be no fractional ADSs issued as part of this transition; instead, holders due fractional amounts will receive cash payments equivalent to their share in the total number of ADSs. This approach ensures that all ADS holders are treated equitably during the modification process.
Next Steps for Investors
Investors will notice the impact of this adjustment represented in their accounts after the effective date of January 30, 2025. Those holding ADSs in book-entry form or via another nominee will not need to take any action. However, holders of certificate form ADSs will receive instructions for exchanging their certificates shortly after the official transition date.
About BioLineRx
BioLineRx is committed to advancing transformative treatments in the realms of oncology and rare diseases. Their flagship product, APHEXDA (motixafortide), has already received positive feedback for its potential application in stem cell mobilization for various treatments. The company’s expertise spans development, regulatory interaction, and commercialization, allowing for systematic progression of innovative therapies from conceptual stages to clinical application.
Frequently Asked Questions
What is the new ratio of ADS to ordinary shares for BioLineRx?
The new ratio is set at 1 ADS for every 600 ordinary shares.
When will this new ratio take effect?
The changes will be effective prior to the market opening on January 30, 2025.
How does this affect the trading price of ADS?
The trading price of the ADS is expected to increase significantly, corresponding to the new ratio, but no guarantees are made regarding specific price levels post-change.
Will all holders of ADS be affected by this change?
No, holders of ordinary shares on the Tel Aviv Stock Exchange will remain unaffected.
What should ADS holders do after the change is implemented?
Those holding ADSs in book-entry form will see automatic updates reflecting the new share ratio in their accounts without needing to take action.
